RU2017145271A - Терапевтическое средство для фиброза - Google Patents
Терапевтическое средство для фиброза Download PDFInfo
- Publication number
- RU2017145271A RU2017145271A RU2017145271A RU2017145271A RU2017145271A RU 2017145271 A RU2017145271 A RU 2017145271A RU 2017145271 A RU2017145271 A RU 2017145271A RU 2017145271 A RU2017145271 A RU 2017145271A RU 2017145271 A RU2017145271 A RU 2017145271A
- Authority
- RU
- Russia
- Prior art keywords
- fibrosis
- amino
- treating
- fibroza
- therapeutic
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 claims 13
- 230000004761 fibrosis Effects 0.000 claims 13
- 238000000034 method Methods 0.000 claims 4
- ORRNXRYWGDUDOG-UHFFFAOYSA-N 4-[2-fluoro-4-[(2-phenylacetyl)carbamothioylamino]phenoxy]-7-methoxy-n-methylquinoline-6-carboxamide Chemical compound C1=CN=C2C=C(OC)C(C(=O)NC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=S)NC(=O)CC1=CC=CC=C1 ORRNXRYWGDUDOG-UHFFFAOYSA-N 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
Claims (8)
1. Способ лечения фиброза, включающий введение 4-[2-фтор-4-[[[(2-фенилацетил) амино] тиоксометил] амино] -фенокси] -7-метокси-N-метил-6-хинолинкарбоксамида или его соли пациенту.
2. Способ лечения фиброза по п.1, где фиброз является фиброзом легких.
3. Способ лечения фиброза по п.1, где фиброз является интерстициальной пневмонией, сопровождаемой фиброзом.
4. Способ лечения фиброза по п. 1, где фиброз представляет собой идиопатический фиброз легких.
5. Применение 4-[2-фтор-4-[[[(2-фенилацетил) амино] тиоксометил] амино] -фенокси] -7-метокси-N-метил-6-хинолинкарбоксамида или его соли для получения лекарства для лечения фиброза.
6. Применение по п. 5, где фиброз является фиброзом легких.
7. Применение по п. 5, где фиброз является интерстициальной пневмонией, сопровождаемой фиброзом.
8. Применение по п. 5, где фиброз является идиопатическим фиброзом легких.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015127788 | 2015-06-25 | ||
| JP2015-127788 | 2015-06-25 | ||
| PCT/JP2016/068902 WO2016208744A1 (ja) | 2015-06-25 | 2016-06-24 | 線維症治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017145271A true RU2017145271A (ru) | 2019-07-25 |
| RU2017145271A3 RU2017145271A3 (ru) | 2019-12-02 |
| RU2729630C2 RU2729630C2 (ru) | 2020-08-11 |
Family
ID=57585165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017145271A RU2729630C2 (ru) | 2015-06-25 | 2016-06-24 | Терапевтическое средство для фиброза |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10449189B2 (ru) |
| EP (2) | EP3315131B1 (ru) |
| JP (3) | JP6974167B2 (ru) |
| KR (1) | KR102647942B1 (ru) |
| CN (2) | CN107708697B (ru) |
| AU (1) | AU2016284531B2 (ru) |
| BR (1) | BR112017028137B1 (ru) |
| CA (1) | CA2990791A1 (ru) |
| DK (1) | DK3315131T3 (ru) |
| ES (1) | ES2928684T3 (ru) |
| HU (1) | HUE060732T2 (ru) |
| MA (1) | MA42266A (ru) |
| MX (2) | MX381792B (ru) |
| MY (1) | MY191219A (ru) |
| PH (1) | PH12017502322B1 (ru) |
| PL (1) | PL3315131T3 (ru) |
| PT (1) | PT3315131T (ru) |
| RU (1) | RU2729630C2 (ru) |
| SG (2) | SG10201912684TA (ru) |
| WO (1) | WO2016208744A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007139608A1 (en) | 2006-03-14 | 2007-12-06 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| US12152246B2 (en) | 2006-03-14 | 2024-11-26 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| SG10201912684TA (en) * | 2015-06-25 | 2020-03-30 | Taiho Pharmaceutical Co Ltd | Therapeutic agent for fibrosis |
| MX2021007061A (es) | 2017-02-15 | 2022-10-07 | Taiho Pharmaceutical Co Ltd | Composición farmacéutica que comprende 4-(2-fluoro-4-(3-(2- fenilacetil)tioureido)fenoxi)-7-metoxi-n-metilquinolina-6-carboxa mida e hidroxipropil-b-ciclodextrina. |
| WO2019049956A1 (ja) | 2017-09-08 | 2019-03-14 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
| KR20210060465A (ko) | 2018-09-18 | 2021-05-26 | 다이호야쿠힌고교 가부시키가이샤 | 아실티오우레아 화합물과 아비라테론의 병용 요법 |
| TWI872203B (zh) * | 2020-02-14 | 2025-02-11 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
| CN115177636A (zh) * | 2022-07-18 | 2022-10-14 | 陕西科美致尚生物科技有限公司 | 一种用于治疗前列腺钙化的组合物及其制备方法与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1074264B1 (en) | 1998-04-28 | 2008-09-17 | Toshikazu Nakamura | Neovascularization inhibitors |
| JP2003238592A (ja) | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| MX2007015679A (es) | 2005-06-30 | 2008-02-21 | Amgen Inc | Inhibidores de quinasa bis-aril y su uso en el tratamiento de inflamacion, angiogenesis y cancer. |
| CA2630884A1 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| ZA200804681B (en) * | 2005-11-30 | 2009-11-25 | Vertex Pharma Inc | Inhibitors of C-Met and uses thereof |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| JP2011500778A (ja) | 2007-10-25 | 2011-01-06 | アストラゼネカ・アクチエボラーグ | ピリジン及びピラジン誘導体−０８３ |
| RU2503664C2 (ru) | 2008-04-10 | 2014-01-10 | Тайхо Фармасьютикал Ко., Лтд. | Производное ацилтиомочевины или его соль, и его применение |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| JP5714030B2 (ja) * | 2010-02-03 | 2015-05-07 | インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン |
| EP3450432A1 (en) | 2010-05-17 | 2019-03-06 | Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| RU2494470C1 (ru) * | 2012-04-04 | 2013-09-27 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") | Способ лечения фиброза легких |
| US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| SG10201912684TA (en) * | 2015-06-25 | 2020-03-30 | Taiho Pharmaceutical Co Ltd | Therapeutic agent for fibrosis |
-
2016
- 2016-06-24 SG SG10201912684TA patent/SG10201912684TA/en unknown
- 2016-06-24 CA CA2990791A patent/CA2990791A1/en active Pending
- 2016-06-24 JP JP2017525457A patent/JP6974167B2/ja active Active
- 2016-06-24 MA MA042266A patent/MA42266A/fr unknown
- 2016-06-24 BR BR112017028137-6A patent/BR112017028137B1/pt active IP Right Grant
- 2016-06-24 MY MYPI2017704204A patent/MY191219A/en unknown
- 2016-06-24 PL PL16814513.4T patent/PL3315131T3/pl unknown
- 2016-06-24 PT PT168145134T patent/PT3315131T/pt unknown
- 2016-06-24 DK DK16814513.4T patent/DK3315131T3/da active
- 2016-06-24 US US15/574,060 patent/US10449189B2/en active Active
- 2016-06-24 KR KR1020177033481A patent/KR102647942B1/ko active Active
- 2016-06-24 WO PCT/JP2016/068902 patent/WO2016208744A1/ja not_active Ceased
- 2016-06-24 SG SG11201709260TA patent/SG11201709260TA/en unknown
- 2016-06-24 RU RU2017145271A patent/RU2729630C2/ru active
- 2016-06-24 EP EP16814513.4A patent/EP3315131B1/en active Active
- 2016-06-24 HU HUE16814513A patent/HUE060732T2/hu unknown
- 2016-06-24 CN CN201680037175.7A patent/CN107708697B/zh active Active
- 2016-06-24 MX MX2017016774A patent/MX381792B/es unknown
- 2016-06-24 CN CN202110067291.6A patent/CN112716952A/zh active Pending
- 2016-06-24 ES ES16814513T patent/ES2928684T3/es active Active
- 2016-06-24 AU AU2016284531A patent/AU2016284531B2/en active Active
- 2016-06-24 EP EP21205221.1A patent/EP3973962A1/en not_active Withdrawn
- 2016-06-24 PH PH1/2017/502322A patent/PH12017502322B1/en unknown
-
2017
- 2017-12-19 MX MX2020012989A patent/MX2020012989A/es unknown
-
2019
- 2019-09-17 US US16/573,362 patent/US10695340B2/en active Active
-
2020
- 2020-06-02 US US16/889,870 patent/US11191759B2/en active Active
-
2021
- 2021-10-29 US US17/513,946 patent/US11690838B2/en active Active
- 2021-11-04 JP JP2021180108A patent/JP7258985B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061284A patent/JP7498827B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX387115B (es) | Métodos para tratar la influenza. | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| BR112015006341A2 (pt) | compostos, composição farmacêutica, método para tratar condição fibrótica, quantidade terapeuticamente efetiva de composto, de sal farmaceuticamente aceitável deste ou de composição farmacêutica e usos das mesmas e de compostos e/ou composição farmacêutica | |
| EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| WO2015187542A8 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| EA201791780A1 (ru) | Ингаляционный раствор тиотропия для небулайзерного распыления | |
| ME02841B (me) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JP2016027060A5 (ru) | ||
| WO2016040169A3 (en) | Mucolytic agents for use in tretaing pulmonary sarcoidosis | |
| EA201691402A1 (ru) | Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| EA033446B1 (ru) | Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта | |
| EA202091446A1 (ru) | Способы лечения хронических воспалительных заболеваний | |
| WO2016057658A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| JP2015516419A5 (ru) | ||
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
| JP2017517561A5 (ru) | ||
| PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof |